Paris-based telehealth company BePATIENT
has partnered with Silicon Valley biosensor company Vital Connect
for a remote patient monitoring system dubbed BeVITAL
. The unusual part is that the Vital Connect sensor, HealthPatchMD, is about the size of a standard bandage–it adheres to the skin by the heart–and transmits multiple vital signs including single-lead ECG, heart rate, RR interval, heart rate variability, respiratory rate, skin temperature, body posture, fall detection and activity including steps. The BePATIENT PC/mobile telehealth platform has a patient facing mobile app (‘Fast Path’) app, currently available in the Apple App Store, with a clinician-facing reporting module. BeVITAL has been piloted already in Europe for post-discharge monitoring of over 80 surgical patients in clinical studies at five hospitals, with two more deployments this summer. In the Americas, the two post-discharge pilots will concentrate on heart failure, in the US at John Muir Medical Center in Walnut Creek and Concord, California and at the Hospital Infantile De Las Californias, Tijuana, Mexico. The latter study will be run by Scripps Translational Science Institute in San Diego.
BePATIENT’s platforms and ‘digital health modules’ are largely used in France, Europe and Australia, and also integrate devices from iHealth, Withings and fitness tracker Fitbit. The Vital Connect Platform is FDA-cleared, CE-marked and Ninsho Certified (Japan). In addition to the HealthPatchMD biosensor, which is reusable up to 500 times, they developed the single-use VitalPatch biosensor marketed in the US and Europe, and being tested by Philips for at-risk hospital patients (ZDNet). Release, KTVU News